Keywords: LDH; lactate dehydrogenase; NK; natural killer cell; TKI; tyrosine kinase inhibitor;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: irAE; immune related adverse event; ECOG PS; European cooperative oncology group performance status; n.s.; not significant; EGFR; epidermal growth factor receptor; ALK; anaplastic lymphoma kinase; PD-L1; programmed death-ligand 1; TKI; tyrosine-kinase inh
Keywords: TKI; Angiogenesis; Immune system; Renal carcinoma; Immunotherapy;
Keywords: Lung cancer; NSCLC; Adenocarcinoma; Sarcomatoid; MET; Exon 14; Mutation; Crizotinib; Tyrosine kinase inhibitor; TKI; Non-small cell;
Keywords: AUC; area under the curve; CE; cost effectiveness; CEAC; cost-effectiveness acceptability curve; CI; confidence interval; DMSIC; Drug and Medical Supply Information Center; DRG; diagnosis-related group; DSA; deterministic sensitivity analysis; EGFR; epide
Keywords: ABC; ATP-binding cassette; ASBT; apical sodium-dependent bile acid transporter; Bamet-UD2; cisplatin-ursodeoxycholic acid derivative; CCA; cholangiocarcinoma; DHMEQ; dehydroxymethyl epoxyquinomicin; EGFR; epidermal growth factor receptor; 5-FU; 5-fluorour
Keywords: ABC; ATP-binding cassette; AKT; V-Akt murine thymoma viral oncogene homolog; ALDH1; aldehyde dehydrogenase 1; AR; androgen receptor; Bad; Bcl-2-associated death promoter; Bak; Bcl-2 homologous antagonist killer; Bax; Bcl-2-associated X protein; Bcl-2; B-c
Keywords: Small molecules; biologics; adverse effects mouth; BP; Bisphosphonates; EGFR; Epidermal growth factor receptor; FDA; Food and Drug Administration; HER2; Human epidermal growth factor receptor 2; HNSCC; Head and neck squamous cell carcinoma; mAbs; Monoclon
Keywords: Spray targeting; Diesel combustion; NOx; Soot; NTP; CA b(a)TDC; Crank Angle before (after) Top Dead Centre; CAD; Crank Angle Degrees; CFD; Computational Fluid Dynamics; DOC; Diesel Oxidation Catalyst; DPF; Diesel Particulate Filter; EGR; Exhaust Gas Recir
Keywords: NSCLC; non-small cell lung cancer; EGFR; epidermal growth factor receptor; OR; odds ratio; HR; hazards ratio; CI; confidence interval; ALK; anaplastic lymphoma kinase; OS; overall survival; NHIS; National Health Insurance Service; NHID; National Health In
Keywords: DFS; disease-free survival; EGFR; epidermal growth factor receptor; Ex19; exon 19 deletion; Ex21; exon 21 L858R; OS; overall survival; RFS; recurrence-free survival; TKI; tyrosine kinase inhibitor; WT; wild-type;
Keywords: α-SMA; α-smooth muscle actin; Ad; adamantane; BMP-7; bone morphogenetic protein 7; CD; β-cyclodextrine; CKD; chronic kidney disease; CPP; cell penetrating peptide; COX-2; cyclooxygenase 2; CTGF; connective tissue growth factor; DAMPs; danger associated
Keywords: ACC; acetyl-CoA carboxylase; ALDOA; aldolase A; AIs; aromatase inhibitors; AMPK; AMP-activated protein kinase; BC; breast cancer; CML; chronic myelogenous leukemia; CT; computed tomography; CPT1; carnitine palmitoyltransferase 1; CRC; colorectal cancer; 2
Keywords: Tyrosine kinase inhibitors; TKI; Lung cancer;
Keywords: NSCLC; non small-cell lung cancer; EGFR; epidermal growth factor receptor; TKI; tyrosine kinase inhibitor; PFS; progression-free survival; ECOG; Eastern Cooperative Oncology Group; RECIST; Response Evaluation Criteria in Solid Tumors; ECG; electrocardiogr
Keywords: EGFR; Epidermal growth factor receptor; TP53; Tumor protein p53; KRAS; Kirsten rat carcoma viral oncogene; ALK; Anaplastic lymphoma kinase; RTK; Protein receptor tyrosine kinase; TKI; Tyrosine kinase inhibitor; PI3K; Phosphatidylinositol 3-kinase; NSCLC;
Keywords: mRCC; PPI; Targeted therapy; TKI; VEGF;
Keywords: SNPs; single-nucleotide polymorphisms; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; ADC; lung adenocarcinoma; LCINS; lung cancer in never-smokers; ALK; anaplastic lymphoma kinase; GWAS; genome-wide association studies; HKU/HA
Keywords: Clinical practice; Metastatic RCC; Registry; TKI; Treatment patterns;
Keywords: HIV; Human Immunodeficiency Virus; CYP; Cytochrome P450; TKI; tyrosine kinase inhibitor; P-gp; P-glycoprotein; OATP; Organic Anion Transporting Polypeptide; INR; International Normalized Ratio; Drug-food interactions; Clinical practice; Cytochrome P450 3A
Keywords: VEGF; Vascular Endothelial Growth Factor; MMP; Matrixmetalloproteinases; uPAR; UrokinasePlasminogen Activator Receptor; Ang-1; Angiotensin-1; TGF-β; Transforming Growth Factor-β; VEGFR; Vascular Endothelial Growth Factor Receptor; TKI; Tyrosine Kinase I
Keywords: ADCC; antibody-dependent cell-mediated cytotoxicity; AKT; protein kinase B; ATP; adenosine triphosphate; cfDNA; circulating free DNA; CISH; chromogenic in-situ hybridization; CTC; circulating tumor cells; EGFR; epithelial growth factor receptor; EMT; epit
Keywords: BM; Kidney; RCC; TKI; Zoledronic acid;
Keywords: Chronic myeloid leukemia; Blast crisis; Disease progression mechanisms; Causal modeling; Bayesian networks; Feedback loops; AP; accelerated phase; BC; blast crisis; CHR; complete hematological response; CML; chronic myeloid leukemia; CP; chronic phase; DA
Keywords: Acute lymphoblastic leukemia; ALL; Allogeneic; Cytogenetics; Dasatinib; Imatinib; Minimal residual disease; MRD; Nilotinib; Philadelphia chromosome positive; Ph+; Ponatinib; Stem cell transplant; TKI; Tyrosine kinase inhibitor;
Keywords: Kidney cancer; mTOR; Retrospective analysis; TKI; VEGF;
Keywords: TME; tumor microenvironment; NHSC; non hematopoietic stromal cells; MSC; mesenchymal stem cells; MF; myofibroblasts; CAF; cancer associated fibroblasts PGE2 prostaglandin E2; VEC; vascular endothelial cells; LEC; lymphatic endothelial cells; PDGFR; platel
Keywords: Metastatic renal cell carcinoma; Clear cell renal cell carcinoma; Non-clear cell renal cell carcinoma; Precision medicine; Personalized medicine; Targeted therapy; TKI; mTOR; PD-1; PD-L1
Keywords: AC; adenocarcinoma; EGFR; epidermal growth factor receptor; ERCC1; Excision repair cross-complementation group 1; LCNEC; large cell neuroendocrine carcinoma; NSCLC; non-small cell lung carcinoma; OS; overall survival; SCLC; small cell lung carcinoma; SST;
Keywords: First-line mRCC treatment; mRCC prescribing preferences; Pazopanib; Sunitinib; TKI;
Keywords: Ab; antibody; ACT; adoptive cell therapy; ANG; angiopoietin; ATP; adenosine triphosphate; BMDC; bone marrow derived cell; CA4P; combretastatin A phosphate; CAF; cancer-associated fibroblast; CCL2; C-C motif ligand 2; CD; cluster differentiation antigen; C
Keywords: AE; adverse event; ALL; acute lymphoblastic leukemia; alloSCT; allogeneic hematopoietic stem cell transplant; AYA; adolescent and young adult; BFM; Berlin-Frankfurt-Münster; CAR-T; chimeric antigen receptor-modified T cell; CCyR; complete cytogenetic r
Keywords: Ang1/2; angiopoietin 1 or 2; BMPR2; Bone morphogenetic protein receptor type 2; CAV-1/2; caveolin-1/2; CHD; congenital heart disease; EC; endothelial cell; ECFC; endothelial colony forming cells; EGR-1; early growth response protein 1; EndoMT; endothelial
Keywords: CAPRI; Ca2+-promoted RAS inactivator; CRMP-2; collapsin response mediator protein-2; CSRD; cysteine/serine-rich domain; CTD; C-terminal domain; ERK; extracellular signal-regulated kinase; FTI; farnesyltransferase inhibitor; FAK1; focal adhesion kinase 1;
Keywords: AM; adrenomedullin; AMF; autocrine motility factor; AML; acute myeloid leukemia; BCL; B-cell lymphoma; BCR; breakpoint cluster region; BM; bone marrow; CCL; chemokine (CâC motif) ligand; CML; chronic myeloid leukemia; ECM; extracellular matrix; EGF; epi
Keywords: Cancer stem cell; Chemotherapy; Chemoresistance; Targeted therapy; 5-FU; 5-fluorouracil; ABCT; ATP-binding cassette transporter; ALDH; Aldehyde dehydrogenase; AML; Acute myeloid leukemia; ASC; Adult stem cell; BCRP or ABCG; Breast cancer resistance protei
Keywords: mRCC; sorafenib; sunitinib; thyroid function; TKI;
Keywords: CR; complete response; CNR; contrast-to-noise ratio; GIST; gastrointestinal stromal tumor; PD; progressive disease; PDGFRA; platelet-derived growth factor receptor A; PET; positron-emission tomography; PFI; progression-free interval; PR; partial response;
Keywords: Tyrosine kinase inhibitors; Drug transporter; Drug interaction; Therapeutic drug monitoring; Skin disorders; ADR; Adverse drug reaction; AUC; Area under the curve; BBB; Blood-brain barrier; BCRP/ABCG2; Breast cancer resistance protein; CNS; Central nerv
Keywords: Glioblastoma; Treatment; Review; Pharmacology; Targeted therapy; Stem cell; AKT; protein kinase B; BBB; blood-brain barrier; BCNU; carmustin; CCNU; lomustin; c-MET; hepatocyte growth factor receptor; EGF(R); epidermal growth factor (receptor); EGFRvIII; e
Keywords: 2DG; 2-deoxy-glucose; 6-AN; aminocicotinamide; ABC; ATP-binding cassette transporter; CSCs; cancer stem cells; DCA; dichloroacetate; G6PD; glucose-6-phosphate dehydrogenase; GLUT; glucose transporter; HIF; hypoxia-inducible factors; HK2; hexokinase 2; Kra
Keywords: EGFR; Erlotinib; TKI; Genetic polymorphisms; Treatment response; Survival;
Keywords: 2 DE; 2-dimensional electrophoresis; ABPP; activity-based protein profiling; BFGF; basic fibroblast growth factor; CML; chronic myeloid leukemia; CRC; colorectal cancer; DIGE; differential in gel electrophoresis; EGF(R); epidermal growth factor (receptor)
Keywords: NGS; CML; ALL; BCR-ABL1; Tyrosine kinase domain; TKI;
Keywords: ALK; anaplastic lymphoma kinase; EGFR; epidermal growth factor receptor; FGFR; fibroblast growth factor receptor; FISH; fluorescence in situ hybridization; MET; mesenchymal epithelial transition; NGS; next-generation sequencing; SQCC; squamous cell carcin
Keywords: JCOG; Japan Clinical Oncology Group; SCLC; small cell lung cancer; ED; extensive disease; OS; overall survival; WJOG; West Japan Oncology Group; NSCLC; non-small-cell lung cancer; EGFR; epidermal growth factor receptor; PFS; progression-free survival; TKI
Keywords: EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; TKI; tyrosine kinase inhibitor; WT; wild type; KRAS; Kirsten RNA associated rat sarcoma 2 virus gene; PTEN; phosphatase and tensin homolog; HGF; hepatocyte growth factor; IGF1R; in
Keywords: ADAM; (a disintegrin and metalloprotease) metallopeptidase; ALPs; alkyl-lysophospholipids; CD24; signal transducer CD24 (glycosylphosphatidylinositol-anchored receptor); CD44; CD44 antigen (receptor for hyaluronic acid); CXCR4; chemokine receptor type 4;
Keywords: 5FU; 5-fluorouracile; ABC; ATP-binding cassette; AUC; area under the curve; BCRP; breast cancer resistance protein; Cmax; maximum (peak) plasma concentration; CYP; cytochrome p450 enzymes; DDI; drug-drug interactions; EIAEDS; enzyme-inducing antiepilept
Keywords: Anti-angiogenesis; Resistance; Targeted therapies; Predictive markers; Autophagy; AKT/PKB; protein kinaseB; BMDCs; bone marrow-derived cells; BVZ; bevacizumab/Avastin; CSC; cancer stem-like cells; EGF; epidermal growth factor; EPC; endothelial progenitor